---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017991"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T16:38:46.312258+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Olema reports Q3 net loss $21.5M, cash $276.9M; OPERA-01 Phase 3 on track

## Summary
- Net loss $21.5M vs $22.7M YoY; cash, equivalents and marketable securities $276.9M.
- R&D expenses $19.5M GAAP ($16.7M non-GAAP) as Phase 3 palazestrant trial advances.
- OPERA-01 Phase 3 monotherapy trial site activation ongoing, first patient expected Q4 2023.
- New palazestrant combination data with CDK4/6 inhibitors to be presented at SABCS Dec 2023.
- Appointed Scott Garland to board; completed financing up to $180M (equity + credit facility).

## SEC filing metadata
- accession: 0001558370-23-017991
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000155837023017991/0001558370-23-017991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000155837023017991/olma-20231107x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017991
- JSON: https://secwatch.observer/filing/0001558370-23-017991.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017991.txt

## Key facts
- Earnings Releases
  Olema Pharmaceuticals, Inc. reported quarter ended September 30, 2023 results: net income $21.5 million.
  - Period: quarter ended September 30, 2023
  - Net income: $21.5 million
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2023, was $21.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750284/000155837023017991/0001558370-23-017991-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.